Journal article
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
Jorge J Castillo, Gilad Itchaki, Jonas Paludo, Marzia Varettoni, Christian Buske, Toby A Eyre, Julio C Chavez, Kenneth H Shain, Samar Issa, M Lia Palomba, Oren Pasvolsky, David Simpson, Dipti Talaulikar, Constantine S Tam, Alessandra Tedeschi, Stephen M Ansell, Lakshmi Nayak, Steven P Treon
BLOOD | AMER SOC HEMATOLOGY | Published : 2019
Abstract
The treatment of patients with Bing-Neel syndrome (BNS) is not standardized. We included patients with Waldenström macroglobulinemia (WM) and a radiologic and/or cytologic diagnosis of BNS treated with ibrutinib monotherapy. Response assessment was based on criteria for BNS from the 8th International Workshop for WM. Survival from BNS diagnosis (BNS survival), survival from ibrutinib initiation to last follow-up or death (ibrutinib survival), and time from ibrutinib initiation to ibrutinib discontinuation for toxicity, progression, or death (event-free survival [EFS]) were estimated. Twenty-eight patients were included in our study. The median age at BNS diagnosis was 65 years. Ibrutinib was..
View full abstractGrants
Funding Acknowledgements
G.I. was awarded a Young Investigator Award at the 10th International Workshop for Waldenstrom Macroglobulinemia for this research. J.J.C. thanks the WMR Fund for support.